BDBM50292978 CHEMBL489095::GSK-962040::N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine

SMILES C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1

InChI Key InChIKey=RZKDEGZIFSJVNA-UHFFFAOYSA-N

Data  7 IC50  3 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 50292978   

TargetCytochrome P450 3A4(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataIC50: 2.60E+4nMAssay Description:Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetCytochrome P450 3A4(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataIC50: 6.90E+4nMAssay Description:Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetCytochrome P450 1A2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP1A2More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetCytochrome P450 2C9(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetCytochrome P450 2C19(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human CYP2C19More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetCytochrome P450 2D6(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataIC50: 3.40E+4nMAssay Description:Inhibition of human CYP2D6More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetMotilin receptor(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataEC50:  12.6nMAssay Description:Agonist activity at human recombinant motilin receptor expressed in CHO cells assessed as increase in intracellular calcium by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetGrowth hormone secretagogue receptor type 1(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataEC50: >1.00E+3nMAssay Description:Agonist activity at human Ghrelin receptorMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataIC50: 1.58E+4nMAssay Description:Binding affinity to human ERGMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2012
Entry Details Article
PubMed
TargetMotilin receptor(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50292978(GSK-962040 | N-(3-Fluorophenyl)-1-[(4-([(3S)-3-met...)
Affinity DataEC50:  970nMAssay Description:Agonist activity at human GPR38 expressed in COS-7 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed